Compare Charles River Laboratories Intl. Inc (CRL) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs RLX Technology Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $227.5 (market cap $11.14B), while RLX Technology Inc trades at $2.03 (market cap $2.42B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 4.6× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | RLX | |
|---|---|---|
Market Cap | $11.14B | $2.42B |
Sector | Health | Technology |
52-Week High | $233.60 | $2.73 |
52-Week Low | $145.57 | $1.79 |
Enterprise Value | $14.00B | $1.05B |
Dividend Yield | — | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
RLX Technology trades at $1.97, up 1.03% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth driven by international expansion, though it missed EPS estimates for three consecutive quarters. RLX maintains strong profitability with a 22.47% net income margin and is debt-free with substantial cash flow from operations.
Outlook is mixed: strong fundamentals and industry growth potential are offset by recent earnings misses and a single analyst hold rating. Key risks include regulatory scrutiny in the vaping sector and execution challenges in global markets. The stock presents a value opportunity but requires monitoring of earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
